GCG and pancreatic neoplasm: Although GLP-1 agonists have lower risk of hypoglycemia compared to sulfonylureas and meglitinides, they work in the same pathway as DPP-4 inhibitors and there are concerns of an increased risk of pancreatitis and pancreatic cancer [7].